

## Special Issue

# Implementation of New Imaging Techniques, Biomarkers and New Treatments in Prostate Cancer

### Message from the Guest Editors

We are living in an era of unprecedented development in prostate cancer, both in the diagnosis of the disease with the introduction of multiparametric magnetic resonance imaging and positron emission tomography (PET) with new radiotracers (PSMA, fluciclovine, etc.), as well as with the implementation of molecular biomarkers (serum and urinary markers, genomic classifiers, genes associated with alterations in DNA repair, mismatch repair, etc.) which have diagnostic and prognostic implications that can allow us to personalize the treatment for our patients. The number of therapeutic options for castration-resistant and metastatic prostate cancer has substantially increased over the last few years. The traditional treatment for these patients (i.e., androgen deprivation therapy) is now considered suboptimal. Moreover, in patients with oligometastatic disease or low tumor burden, metastasis-directed therapy combined with systemic treatments is another area of growing interest. This Special Issue aims to explore the technological and therapeutic advances that already have a clinical use or that can transform the diagnostic and treatment paths of prostate cancer in the coming years.

### Guest Editors

Dr. Felipe Couñago

Radiation Oncologist, National Clinical Director GenesisCare Spain, Vithas La Milagrosa and San Francisco de Asis Hospitals, 28002 Madrid, Spain

Dr. Thomas Zilli

Dept Radiat Oncol, University of Geneva, Geneva, Switzerland

Dr. Fernando López Campos

Dept Radiat Oncol, Hospital Universitario Ramon y Cajal, Madrid, Spain

### Deadline for manuscript submissions

closed (31 October 2022)



## Biomedicines

an Open Access Journal  
by MDPI

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/101911](https://mdpi.com/si/101911)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).